Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the first peer-reviewed publication of the Phase 3 portion of its pivotal, double-blind, randomized, placebo-controlled.
WHO and MPP announce technology transfer license to enable greater patient accessto multiple essential diagnostics pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
First to Gaza, where WHO continues to face extreme challenges in supporting the health system and health workers. As of today, over 100,000 Gazans are either dead, injured or missing and presumed dead. WHO has faced great difficulty even to reach hospitals in southern Gaza. Heavy fighting has been reported near hospitals in Khan Younis,
WHO, MPP Enable Wider Patient Access to Essential Diagnostics miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
WHO and the Medicines Patent Pool (MPP) announce a license agreement with SD Biosensor Inc., a global in-vitro diagnostic company, to provide sublicensees with the right, know-how and material to manufacture SDB’s rapid diagnostic testing (RDT) technology. The transparent, non-exclusive license agreement, negotiated under the auspices of the COVID-19 Technology Access Pool (C-TAP), represents an important milestone in the evolution of the C-TAP initiative as it enables the manufacture of